Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fine-mapping genomic loci refines bipolar disorder risk genes

  • Koromina, Maria|||0000-0001-8843-082X
  • Ravi, Ashvin
  • Panagiotaropoulou, Georgia
  • Schilder, Brian M.|||0000-0001-5949-2191
  • Humphrey, Jack
  • Braun, Alice|||0000-0003-1145-0261
  • Bigdeli, Tim B.|||0000-0003-2215-5946
  • Chatzinakos, Chris
  • Coombes, Brandon J.|||0000-0003-4322-5923
  • Kim, Jaeyoung|||0000-0001-6983-7907
  • Liu, Xiaoxi|||0000-0002-1933-8613
  • Terao, Chikashi|||0000-0002-6452-4095
  • O'Connell, Kevin S.|||0000-0002-6865-8795
  • Adams, Mark J
  • Adolfsson, Rolf
  • Alda, Martin|||0000-0001-9544-3944
  • Alfredsson, Lars|||0000-0003-1688-6697
  • Andlauer, Till F. M.|||0000-0002-2917-5889
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Antoniou, Anastasia
  • Baune, Bernhard T.|||0000-0001-6548-426X
  • Bengesser, Susanne
  • Biernacka, Joanna
  • Boehnke, Michael|||0000-0002-6442-7754
  • Bosch, Rosa|||0000-0002-7596-183X
  • Cairns, Murray J.
  • Carr, Vaughan J.
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Catts, Stanley
  • Cichon, Sven|||0000-0002-9475-086X
  • Corvin, Aiden
  • Craddock, Nicholas
  • Dafnas, Konstantinos
  • Dalkner, Nina
  • Dannlowski, Udo|||0000-0002-0623-3759
  • Degenhardt, Franziska
  • Di Florio, Arianna
  • Dikeos, Dimitris
  • Fellendorf, Frederike Tabea
  • Ferentinos, Panagiotis|||0000-0001-8531-5623
  • Forstner, Andreas J.
  • Forty, Liz|||0000-0002-4349-8414
  • Frye, Mark
  • Fullerton, Janice M.|||0000-0003-4014-4490
  • Gawlik, Micha
  • Gizer, Ian R.
  • Gordon-Smith, Katherine
  • Green, Melissa J.
  • Grigoroiu-Serbanescu, Maria
  • Guzman-Parra, Jose|||0000-0002-1463-6435
  • Hahn, Tim|||0000-0002-8929-4134
  • Henskens, Frans
  • Hillert, Jan|||0000-0002-7386-6732
  • Jablensky, Assen V.
  • Jones, Lisa|||0000-0002-5122-8334
  • Jones, Ian
  • Jonsson, Lina
  • Kelsoe, John R.
  • Kircher, Tilo|||0000-0002-2514-2625
  • Kirov, George|||0000-0002-3427-3950
  • Kittel-Schneider, Sarah|||0000-0003-3057-6150
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Landén, Mikael|||0000-0002-4496-6451
  • Leboyer, Marion|||0000-0001-5473-3697
  • Lenger, Melanie
  • Lissowska, Jolanta
  • Lochner, Christine|||0000-0002-4766-3704
  • Loughland, Carmel
  • MacIntyre, Donald J.|||0000-0001-6963-1335
  • Martin, Nicholas G.|||0000-0003-4069-8020
  • Maratou, Eirini
  • Mathews, Carol A.|||0000-0003-2208-7058
  • Mayoral-Cleries, Fermín
  • McElroy, Susan L.
  • McGregor, Nathaniel|||0000-0001-7195-4993
  • McIntosh, Andrew M.|||0000-0002-0198-4588
  • McQuillin, Andrew|||0000-0003-1567-2240
  • Michie, Patricia|||0000-0002-4169-8519
  • Mitchell, Philip B.
  • Moutsatsou, Paraskevi
  • Mowry, Bryan J.|||0000-0002-4115-5645
  • Müller-Myhsok, Bertram
  • Myers, Richard M.
  • Nenadić, Igor|||0000-0002-0749-7473
  • Nievergelt, Caroline M.
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Nurnberger, John
  • O'Donovan, Michael C.|||0000-0001-7073-2379
  • 'Donovan, Claire O.
  • Ophoff, Roel A.
  • Owen, Michael J.
  • Pantelis, Christos|||0000-0002-9565-0238
  • Pato, Carlos|||0000-0002-5858-266X
  • Pato, Michele T.
  • Patrinos, George P.
  • Pawlak, Joanna M.
  • Perlis, Roy H.|||0000-0002-5862-6757
  • Porichi, Evgenia
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Reif, Andreas|||0000-0002-0992-634X
  • Reininghaus, Eva Z.
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Rietschel, Marcella|||0000-0002-5236-6149
  • Schall, Ulrich
  • Schofield, Peter R.|||0000-0003-2967-9662
  • Schulze, Thomas G.
  • Scott, Laura J.|||0000-0002-4886-5084
  • Scott, Rodney J.|||0000-0001-7724-3404
  • Serretti, Alessandro
  • Smoller, Jordan W.|||0000-0002-0381-6334
  • Świątkowska, Beata
  • Soler Artigas, María|||0000-0002-3213-1107
  • Stein, Dan J.|||0000-0001-7218-7810
  • Streit, Fabian|||0000-0003-1080-4339
  • Toma, Claudio|||0000-0003-3901-7507
  • Tooney, Paul
  • Vawter, Marquis P.
  • Vieta, Eduard|||0000-0002-0548-0053
  • Vincent, John B.
  • Waldman, Irwin D.|||0000-0002-6862-1837
  • Weickert, Cynthia Shannon
  • Weickert, Thomas
  • Witt, Stephanie H.|||0000-0002-1571-1468
  • Hong, Kyung Sue
  • Ikeda, Masashi|||0000-0001-6237-2449
  • Iwata, Nakao|||0000-0003-3189-6076
  • Won, Hong Hee
  • Edenberg, Howard J.|||0000-0003-0344-9690
  • Ripke, Stephan|||0000-0003-3622-835X
  • Raj, Towfique|||0000-0002-9355-5704
  • Coleman, Jonathan R.I.
  • Mullins, Niamh
Bipolar disorder is a heritable mental illness with complex etiology. While the largest published genome-wide association study identified 64 bipolar disorder risk loci, the causal SNPs and genes within these loci remain unknown. We applied a suite of statistical and functional fine-mapping methods to these loci and prioritized 17 likely causal SNPs for bipolar disorder. We mapped these SNPs to genes and investigated their likely functional consequences by integrating variant annotations, brain cell-type epigenomic annotations, brain quantitative trait loci and results from rare variant exome sequencing in bipolar disorder. Convergent lines of evidence supported the roles of genes involved in neurotransmission and neurodevelopment, including SCN2A, TRANK1, DCLK3, INSYN2B, SYNE1, THSD7A, CACNA1B, TUBBP5, FKBP2, RASGRP1, FURIN, FES, MED24 and THRA among others in bipolar disorder. These represent promising candidates for functional experiments to understand biological mechanisms and therapeutic potential. Additionally, we demonstrated that fine-mapping effect sizes can improve performance of bipolar disorder polygenic risk scores across diverse populations and present a high-throughput fine-mapping pipeline.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Shared genetic architecture between attention-deficit/hyperactivity disorder and lifespan

  • Vilar-Ribó, Laura
  • Cabana-Domínguez, Judit
  • Martorell, Lourdes
  • Ramos-Quiroga, Josep Antoni
  • Sanchez-Roige, Sandra
  • Palmer, Abraham A.
  • Vilella, Elisabet
  • Ribasés, Marta
  • Muntané, Gerard
  • Soler Artigas, María
© The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/., There is evidence linking ADHD to a reduced life expectancy. The mortality rate in individuals with ADHD is twice that of the general population and it is associated with several factors, such as unhealthy lifestyle behaviors, social adversity, and mental health problems that may in turn increase mortality rates. Since ADHD and lifespan are heritable, we used data from genome-wide association studies (GWAS) of ADHD and parental lifespan, as proxy of individual lifespan, to estimate their genetic correlation, identify genetic loci jointly associated with both phenotypes and assess causality. We confirmed a negative genetic correlation between ADHD and parental lifespan (rg = −0.36, P = 1.41e−16). Nineteen independent loci were jointly associated with both ADHD and parental lifespan, with most of the alleles that increased the risk for ADHD being associated with shorter lifespan. Fifteen loci were novel for ADHD and two were already present in the original GWAS on parental lifespan. Mendelian randomization analyses pointed towards a negative causal effect of ADHD liability on lifespan (P = 1.54e−06; Beta = −0.07), although these results were not confirmed by all sensitivity analyses performed, and further evidence is required. The present study provides the first evidence of a common genetic background between ADHD and lifespan, which may play a role in the reported effect of ADHD on premature mortality risk. These results are consistent with previous epidemiological data describing reduced lifespan in mental disorders and support that ADHD is an important health condition that could negatively affect future life outcomes., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-00444 and 2017SGR-1461), the Instituto de Salud Carlos III (PI18/01788, P19/01224, PI20/00041, PI21/00612, PI22/00464, FI18/00285 to LVR and CP22/00128 to MSA), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to MSA and RYC2021-031324-I to JCD); the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014–2020) under grant agreements no. 728018 (Eat2beNICE), no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN) and the ECNP Network ‘ADHD across the Lifespan’ and “la Marató de TV3” (202228-30 and 202228-31). SSR was supported by funds from the California Tobacco-Related Disease Research Program (TRDRP; Grant Number T29KT0526 and T32IR5226), and NIH/NIDA DP1DA054394. AAP was supported by NIH grant P50DA037844 and R01AA029688 and Tobacco-Related Disease Research Program Grant number: 28IR-0070., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Common and rare variant contributions to discontinuation of stimulant treatment in ADHD

  • Thirstrup, Janne Pia
  • Duan, Jinjie
  • Albiñana, Clara
  • Dalsgaard, Søren
  • Ribases, Marta
  • Soler Artigas, María
Attention-deficit hyperactivity disorder; Personalized medicine; Pharmacogenomics, Trastorn per dèficit d'atenció amb hiperactivitat; Medicina personalitzada; Farmacogenòmica, Trastorno por déficit de atención con hiperactividad; Medicina personalizada; Farmacogenómica, Stimulants are the first-line pharmacological treatment for ADHD and generally effective, yet 35–61% of individuals discontinue treatment within a year. We investigated the contribution of common and rare genetic variants to early stimulant discontinuation using data from 18,362 individuals with ADHD (31% female) initiating stimulants in iPSYCH, a Danish population-based case-cohort linked to national registers. Discontinuation was defined as a ≥ 180-day gap between dispensations within one year of initiation. We examined genetic differences by age groups, estimated SNP-heritability (h2SNP), conducted genome-wide association studies (GWAS), polygenic score (PGS) analyses, and assessed associations with protein truncating variants (PTV). Within one year, 7102 individuals (39%) had discontinued stimulants. Age-stratified analyses (cut-off: age 16) revealed low genetic correlation (r₉ = 0.23, 95% CI: –0.37, 0.83) between children and adolescents/adults. The h²snp for discontinuation was 0.06 (95% CI: 0.02, 0.11) overall, 0.08 (95% CI: 0.02, 0.14) in children, and 0.14 (95% CI: 0.02, 0.27) in adolescents/adults. No genome-wide significant loci were identified overall or in adolescents/adults; however, one locus (SLC5A12, chromosome 11) reached genome-wide significance in children. Ten of 36 PGSs were associated with discontinuation, with higher psychiatric risk PGSs predicting increased discontinuation, while educational attainment and BMI PGSs showed divergent effects by age. Reduced burden of dopamine-related PTVs was nominally associated with discontinuation, particularly in adolescents/adults. These findings suggest modest contributions of both common and rare variants to stimulant discontinuation in ADHD and point to potential developmental differences in genetic architecture., This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 965381 (TIMESPAN). This research reflects only the authors’ view, and the European Commission is not responsible for any use that may be made of the information it contains. Ditte Demontis was supported by the Novo Nordisk Foundation (NNF20OC0065561, NNF21SA0072102, NNF23OC0083657), the Lundbeck Foundation (R344-2020-1060). The iPSYCH team was supported by grants from the ISCIII Lundbeck Foundation (R102-A9118, R155-2014-1724, and co-funded R248-2017-2003), NIH/NIMH (1R01MH124851-01 to Anders D. Børglum), and the Universities and University Hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was supported by the Novo Nordisk Foundation. High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark (grant to Anders D. Børglum). Søren Dalsgaard was supported by Sawmill-owner Jeppe Juhl’s and wife Ovita Juhl’s Fund, The Capital Region (grant No 22042850), and Greater Copenhagen Health Science Partners (CAG Precision Psychiatry, A7763). Marta Soler Artigas acknowledges a Miguel Servet contract (CP22/00128) awarded by the Instituto de Salud Carlos III and co-funded by the European Union Found: Fondo Social Europeo Plus, FSE + . We acknowledge The Swedish Twin Registry for access to data. The Swedish Twin Registry is managed by Karolinska Institutet and receives funding through the Swedish Research Council under the grant no 2021-00180.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Remote monitoring of wide-ranging real-world changes in adults following ADHD medication initiation

  • Zhang, Yuezhou
  • Veerakanjana, Kanyakorn
  • Sankesara, Heet
  • Marriott, Hannah
  • Barnes, Alice
  • Denyer, Hayley
  • Ramos-Quiroga, Josep Antoni
Remote monitoring; ADHD, Monitorització remota; TDAH, Monitorización remota; TDAH, While attention-deficit/hyperactivity disorder (ADHD) medication is effective for core symptoms, its broader and progressive impacts remain underexplored. This study evaluated real-world changes in ADHD symptoms and impairments, co-occurring psychiatric symptoms, physical measures, and health behaviors following ADHD medication initiation in adults. Data were drawn from a remote monitoring cohort recruited from adult ADHD clinic waiting lists in the United Kingdom and Spain. Participants completed 4-weekly smartphone-based self-reports and continuously wore a wearable device to monitor behaviors such as physical activity and sleep. We additionally developed novel wearable-derived features to approximate restlessness. A subset of 176 participants with valid baseline (off-medication) and up to three 4-weekly on-medication assessments was included. Compared to the off-medication phase, the on-medication phase was significantly associated with improvements in ADHD symptoms and impairments, as well as reductions in depression, anxiety, irritability, and aggression. Additional changes included reduced alcohol use, healthier diet, elevated heart rate, lower blood pressure, reduced waist circumference, increased physical activity, less restlessness, and improved sleep quality. Several domains showed significant progressive changes, including continued improvements in ADHD symptoms, impairments, and irritability; rising heart rate; declining body weight; and delayed sleep timing. These findings suggest ADHD medication in adults is associated with broad real-world benefits alongside some potential concerns, such as elevated heart rate and delayed sleep. This study highlights the potential of remote monitoring technologies to capture multidimensional treatment responses in daily life and provides a foundation for future research to support both clinical care and self-management in ADHD., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965381. This report reflects only the authors’ views and the Commission is not responsible for any use that may be made of the information it contains.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genetic architecture of ADHD and overlap with other psychiatric disorders and cognition-related phenotypes

  • hartman, catharina
  • Larsson, Henrik
  • Ribases, Marta
  • Mitjans, Marina
  • Soler Artigas, María
  • Demontis, Ditte
  • Ramos-Quiroga, Josep Antoni
Trastorno por déficit de atención e hiperactividad; Comorbilidad; Genética de trastornos cruzados, Trastorn per dèficit d'atenció i hiperactivitat; Comorbiditat; Genètica de trastorns creuats, Attention-deficit/hyperactivity disorder; Comorbidity; Cross-disorder genetics, Attention-deficit/hyperactivity disorder (ADHD) co-occurs with many other psychiatric disorders and traits. In this review, we summarize and interpret the existing literature on the genetic architecture of these comorbidities based on hypothesis-generating approaches. Quantitative genetic studies indicate that genetic factors play a substantial role in the observed co-occurrence of ADHD with many different disorders and traits. Molecular genetic correlations derived from genome-wide association studies and results of studies based on polygenic risk scores confirm the general pattern but provide effect estimates that are smaller than those from twin studies. The identification of the specific genetic variants and biological pathways underlying co-occurrence using genome-wide approaches is still in its infancy. The first analyses of causal inference using genetic data support causal relationships between ADHD and comorbid disorders, although bidirectional effects identified in some instances point to complex relationships. While several issues in the methodology and inferences from the results are still to be overcome, this review shows that the co-occurrence of ADHD with many psychiatric disorders and traits is genetically interpretable., This research has received funding from the EU’s Horizon 2020 research and innovation program under grant agreements no. 667302 (CoCA), 728018 (Eat2beNICE) and 2020604 (TIMESPAN) and from the ECNP Network ‘ADHD across the Lifespan' (https://www.ecnp.eu/researchinnovation/ECNP-networks/List-ECNP-Networks/). B Cormand has also been supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (PID2021-1277760B-I100), the Ministerio de Sanidad, Servicios Sociales e Igualdad/Plan Nacional Sobre Drogas (PNSD-2017I050), Fundació La Marató de TV3 (202218-31), Generalitat de Catalunya/AGAUR (2021-SGR-1093), ICREA Academia 2021 and the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 841899 (GRASAD) and 101028810 (ATTENTIVE). M Ribasés was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE), by the Instituto de Salud Carlos III (PI20/00041, CP09/00119 and CPII15/00023), by the Pla estratègic de recerca i innovació en salut (PERIS), Generalitat de Catalunya (METAL-Cat; SLT006/17/287), by the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2017SGR1461) and by Fundació La Marató de TV3 (202228-30, 202228-31). JA Ramos-Quiroga was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE). M Mitjans was supported by Horizon 2020 Marie Sklodowska-Curie Individual Fellowship from the European Commission under grant agreement no. 841899 (GRASAD), the MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR” (RYC2021-033573-I), Ministerio de Ciencia e Innovación (PID2022-139740OA-100) and the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2021-SGR-1093). M Soler Artigas was supported by the Instituto de Salud Carlos III (P19/01224, PI22/00464 and CP22/00128) and by the European Regional Development Fund. B Franke and A Reif were also supported by funding from the EU’s Horizon 2020 research and innovation program under grant agreement no. 847879 (PRIME). B Franke also received relevant funding from the Netherlands Organization for Scientific Research (NWO) for the GUTS project (grant 024.005.011). D Demontis is supported by the Novo Nordisk Foundation (NNF20OC0065561 and NNF21SA0072102), the Lundbeck Foundation (R344-2020-1060), the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 965381 (TIMESPAN). AD Børglum was supported by the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003). Research reported in this publication was also supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R01MH124851. The content of the publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or any of the other funding organisations mentioned here.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Perceptions of adults with ADHD on pharmacological treatment initiation and subsequent adherence: a thematic analysis

  • Barnes, Alice
  • Denyer, Hayley
  • Simblett, Sara
  • Nordby, Emilie S
  • Bilbow OBE, Andrea
  • Hayashi, Wakaho
  • Ramos-Quiroga, Josep Antoni
ADHD; Pharmacological treatment; Treatment engagement, TDAH; Tractament farmacològic; Compromís amb el tractament, TDAH; Tratamiento farmacológico; Compromiso con el tratamiento, Background Following a diagnosis of attention deficit hyperactivity disorder (ADHD), many engage with pharmacological treatments to manage symptoms. However, despite efficacy in short-term ADHD symptom improvements, approximately half of adults discontinue pharmacological treatment within the first year, while others do not entirely adhere to treatment as prescribed. This study aimed to investigate experiences of adults with ADHD in the first year of pharmacological treatment, and how this impacted treatment engagement. Method Twenty-five adults with ADHD completed semi-structured interviews. The interviews investigated perspectives of pharmacological treatment including response to medication, experiences of titration, treatment adherence and decisions for (dis)continuation. Inductive thematic analysis was conducted to generate themes. Results Analysis generated four themes pertaining to pharmacological treatment engagement. (1) Processing diagnosis reflected the processing of one’s diagnosis throughout treatment. (2) Managing expectations outlined how expectations at the outset of treatment can impact perceptions of treatment efficacy. (3) Accessing support highlighted areas of pharmacological treatment in which many felt support was lacking and the impact; (4) Balancing costs and benefits outlined the process that individuals undertook when balancing whether medication was worth continuing. Conclusions This study contextualised the high rates of treatment non-adherence and discontinuation for adults with ADHD, highlighting how ongoing processing of the diagnosis, high expectations of the medication’s impact, available guidance from healthcare services and the ultimate balance of positives against negatives, contribute to an individual’s treatment compliance and continuation. Ultimately, this study highlights the need for personalised treatment and the importance of the availability also of non-pharmacological treatment options., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965381. This report reflects only the authors’ views and the Commission is not responsible for any use that may be made of the information it contains.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The association between type 2 diabetes and attention- deficit/hyperactivity disorder: A systematic review, meta-analysis, and population-based sibling study

  • Zhang, Le
  • Yao, Honghui
  • Jendle, Johan
  • Ribases Haro, Marta
  • Garcia-Argibay, Miguel
  • Li, Lin
  • Du Rietz, Ebba
  • Ramos-Quiroga, Josep Antoni
Attention deficit hyperactivity disorder; Cardiovascular risk factors; Type 2 diabetes, Trastorno por déficit de atención con hiperactividad; Factores de riesgo cardiovascular; Diabetes tipo 2, Trastorn per dèficit d'atenció amb hiperactivitat; Factors de risc cardiovascular; Diabetis tipus 2, We conducted a systematic review and a meta-analysis to quantitatively summarize evidence on the association between attention-deficit/hyperactivity disorder (ADHD) and type 2 diabetes (T2D). Moreover, a register-based sibling study was conducted to simultaneously control for confounding factors. A systematic search identified four eligible observational studies (N = 5738,287). The meta-analysis showed that individuals with ADHD have a more than doubled risk of T2D when considering adjusted estimates (OR=2.29 [1.48–3.55], d=0.46). Results from the register-based Swedish data showed a significant association between ADHD and T2D (HR=2.35 [2.14–2.58]), with substance use disorder, depression, and anxiety being the main drivers of the association, and cardiovascular and familiar risk playing a smaller role. While results from the meta-analysis provide evidence for an increased risk of T2D in individuals with ADHD, the register-based analyses show that the association between ADHD and T2D is largely explained by psychiatric comorbidities. Pending further evidence of causal association, our findings suggest that early identification and treatment of ADHD comorbidities might greatly reduce the risk of developing T2D in individuals with ADHD., The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965381. This report reflects only the author’s view, and the European Union is not responsible for any use that may be made of the information it contains. Henrik Larsson acknowledges financial support from the Swedish Research Council (2018-02599) and the Swedish Brain Foundation (FO2021-0115). Zheng Chang acknowledges financial support from the Swedish Council for Health, Working Life and Welfare (2019-00176). Ebba Du Rietz was supported by grant PD20-0036 from the Swedish Society for Medical Research (SSMF), Funds from the Strategic Research Program in Epidemiology at Karolinska Institutet, Fredrik & Ingrid Thurings Stiftelse and Fonden för Psykisk Hälsa.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

ADHD Remote Technology study of cardiometabolic risk factors and medication adherence (ART-CARMA): a multi-centre prospective cohort study protocol

  • Folarin, Amos A
  • Ramos Sayalero, Carolina
  • Nemeth, Petra
  • Denyer, Hayley
  • Bilbow OBE, Andrea
  • Ramos-Quiroga, Josep Antoni
Attention deficit hyperactivity disorder; Digital phenotyping; Remote monitoring, Trastorno por déficit de atención con hiperactividad; Fenotipado digital; Monitoreo remoto, Transtorn per dèficit d'atenció amb hiperactivitat; Fenotipat digital; Monitorització remota, Background Emerging evidence points at substantial comorbidity between adult attention deficit hyperactivity disorder (ADHD) and cardiometabolic diseases, but our understanding of the comorbidity and how to manage cardiometabolic disease in adults with ADHD is limited. The ADHD Remote Technology study of cardiometabolic risk factors and medication adherence (ART-CARMA) project uses remote measurement technology to obtain real-world data from daily life to assess the extent to which ADHD medication treatment and physical activity, individually and jointly, may influence cardiometabolic risks in adults with ADHD. Our second main aim is to obtain valuable real-world data on adherence to pharmacological treatment and its predictors and correlates during daily life from adults with ADHD. Methods ART-CARMA is a multi-site prospective cohort study within the EU-funded collaboration ‘TIMESPAN’ (Management of chronic cardiometabolic disease and treatment discontinuity in adult ADHD patients) that will recruit 300 adults from adult ADHD waiting lists. The participants will be monitored remotely over a period of 12 months that starts from pre-treatment initiation. Passive monitoring, which involves the participants wearing a wrist-worn device (EmbracePlus) and downloading the RADAR-base Passive App and the Empatica Care App on their smartphone, provides ongoing data collection on a wide range of variables, such as physical activity, sleep, pulse rate (PR) and pulse rate variability (PRV), systolic peaks, electrodermal activity (EDA), oxygen saturation (SpO2), peripheral temperature, smartphone usage including social connectivity, and the environment (e.g. ambient noise, light levels, relative location). By combining data across these variables measured, processes such as physical activity, sleep, autonomic arousal, and indicators of cardiovascular health can be captured. Active remote monitoring involves the participant completing tasks using a smartphone app (such as completing clinical questionnaires or speech tasks), measuring their blood pressure and weight, or using a PC/laptop (cognitive tasks). The ART system is built on the RADAR-base mobile-health platform. Discussion The long-term goal is to use these data to improve the management of cardiometabolic disease in adults with ADHD, and to improve ADHD medication treatment adherence and the personalisation of treatment., The ART-CARMA study has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965381. This communication reflects the views of the authors, and the European Commission is not responsible for any use that may be made of the information it contains. HD is supported by the UK Medical Research Council (MR/N013700/1) and King’s College London member of the MRC Doctoral Training Partnership in Biomedical Sciences.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic architecture of ADHD and overlap with other psychiatric disorders and cognition-related phenotypes

  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Mitjans, M.
  • Hartman, CA.
  • Artigas, M. Soler
  • Demontis, Ditte|||0000-0001-9124-2766
  • Larsson, Henrik
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Kuntsi, J.
  • Faraone, Stephen V.|||0000-0002-9217-3982
  • Børglum, AD.
  • Reif, Andreas|||0000-0002-0992-634X
  • Franke, Barbara|||0000-0003-4375-6572
  • Cormand, Bru|||0000-0001-5318-4382
Attention-deficit/hyperactivity disorder (ADHD) co-occurs with many other psychiatric disorders and traits. In this review, we summarize and interpret the existing literature on the genetic architecture of these comorbidities based on hypothesis-generating approaches. Quantitative genetic studies indicate that genetic factors play a substantial role in the observed co-occurrence of ADHD with many different disorders and traits. Molecular genetic correlations derived from genome-wide association studies and results of studies based on polygenic risk scores confirm the general pattern but provide effect estimates that are smaller than those from twin studies. The identification of the specific genetic variants and biological pathways underlying co-occurrence using genome-wide approaches is still in its infancy. The first analyses of causal inference using genetic data support causal relationships between ADHD and comorbid disorders, although bidirectional effects identified in some instances point to complex relationships. While several issues in the methodology and inferences from the results are still to be overcome, this review shows that the co-occurrence of ADHD with many psychiatric disorders and traits is genetically interpretable.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Perceptions of adults with ADHD on pharmacological treatment initiation and subsequent adherence: a thematic analysis

  • Barnes, Alice
  • Denyer, Hayley
  • Simblett, Sara
  • Nordby, Emilie S
  • Bilbow OBE, Andrea
  • Hayashi, Wakaho
  • Ramos-Quiroga, Josep Antoni
ADHD; Pharmacological treatment; Treatment engagement, TDAH; Tractament farmacològic; Compromís amb el tractament, TDAH; Tratamiento farmacológico; Compromiso con el tratamiento, Background Following a diagnosis of attention deficit hyperactivity disorder (ADHD), many engage with pharmacological treatments to manage symptoms. However, despite efficacy in short-term ADHD symptom improvements, approximately half of adults discontinue pharmacological treatment within the first year, while others do not entirely adhere to treatment as prescribed. This study aimed to investigate experiences of adults with ADHD in the first year of pharmacological treatment, and how this impacted treatment engagement. Method Twenty-five adults with ADHD completed semi-structured interviews. The interviews investigated perspectives of pharmacological treatment including response to medication, experiences of titration, treatment adherence and decisions for (dis)continuation. Inductive thematic analysis was conducted to generate themes. Results Analysis generated four themes pertaining to pharmacological treatment engagement. (1) Processing diagnosis reflected the processing of one’s diagnosis throughout treatment. (2) Managing expectations outlined how expectations at the outset of treatment can impact perceptions of treatment efficacy. (3) Accessing support highlighted areas of pharmacological treatment in which many felt support was lacking and the impact; (4) Balancing costs and benefits outlined the process that individuals undertook when balancing whether medication was worth continuing. Conclusions This study contextualised the high rates of treatment non-adherence and discontinuation for adults with ADHD, highlighting how ongoing processing of the diagnosis, high expectations of the medication’s impact, available guidance from healthcare services and the ultimate balance of positives against negatives, contribute to an individual’s treatment compliance and continuation. Ultimately, this study highlights the need for personalised treatment and the importance of the availability also of non-pharmacological treatment options., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965381. This report reflects only the authors’ views and the Commission is not responsible for any use that may be made of the information it contains.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Common and rare variant contributions to discontinuation of stimulant treatment in ADHD

  • Thirstrup, Janne Pia
  • Duan, Jinjie
  • Albiñana, Clara
  • Dalsgaard, Søren
  • Ribases, Marta
  • Soler Artigas, María
Attention-deficit hyperactivity disorder; Personalized medicine; Pharmacogenomics, Trastorn per dèficit d'atenció amb hiperactivitat; Medicina personalitzada; Farmacogenòmica, Trastorno por déficit de atención con hiperactividad; Medicina personalizada; Farmacogenómica, Stimulants are the first-line pharmacological treatment for ADHD and generally effective, yet 35–61% of individuals discontinue treatment within a year. We investigated the contribution of common and rare genetic variants to early stimulant discontinuation using data from 18,362 individuals with ADHD (31% female) initiating stimulants in iPSYCH, a Danish population-based case-cohort linked to national registers. Discontinuation was defined as a ≥ 180-day gap between dispensations within one year of initiation. We examined genetic differences by age groups, estimated SNP-heritability (h2SNP), conducted genome-wide association studies (GWAS), polygenic score (PGS) analyses, and assessed associations with protein truncating variants (PTV). Within one year, 7102 individuals (39%) had discontinued stimulants. Age-stratified analyses (cut-off: age 16) revealed low genetic correlation (r₉ = 0.23, 95% CI: –0.37, 0.83) between children and adolescents/adults. The h²snp for discontinuation was 0.06 (95% CI: 0.02, 0.11) overall, 0.08 (95% CI: 0.02, 0.14) in children, and 0.14 (95% CI: 0.02, 0.27) in adolescents/adults. No genome-wide significant loci were identified overall or in adolescents/adults; however, one locus (SLC5A12, chromosome 11) reached genome-wide significance in children. Ten of 36 PGSs were associated with discontinuation, with higher psychiatric risk PGSs predicting increased discontinuation, while educational attainment and BMI PGSs showed divergent effects by age. Reduced burden of dopamine-related PTVs was nominally associated with discontinuation, particularly in adolescents/adults. These findings suggest modest contributions of both common and rare variants to stimulant discontinuation in ADHD and point to potential developmental differences in genetic architecture., This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 965381 (TIMESPAN). This research reflects only the authors’ view, and the European Commission is not responsible for any use that may be made of the information it contains. Ditte Demontis was supported by the Novo Nordisk Foundation (NNF20OC0065561, NNF21SA0072102, NNF23OC0083657), the Lundbeck Foundation (R344-2020-1060). The iPSYCH team was supported by grants from the ISCIII Lundbeck Foundation (R102-A9118, R155-2014-1724, and co-funded R248-2017-2003), NIH/NIMH (1R01MH124851-01 to Anders D. Børglum), and the Universities and University Hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was supported by the Novo Nordisk Foundation. High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark (grant to Anders D. Børglum). Søren Dalsgaard was supported by Sawmill-owner Jeppe Juhl’s and wife Ovita Juhl’s Fund, The Capital Region (grant No 22042850), and Greater Copenhagen Health Science Partners (CAG Precision Psychiatry, A7763). Marta Soler Artigas acknowledges a Miguel Servet contract (CP22/00128) awarded by the Instituto de Salud Carlos III and co-funded by the European Union Found: Fondo Social Europeo Plus, FSE + . We acknowledge The Swedish Twin Registry for access to data. The Swedish Twin Registry is managed by Karolinska Institutet and receives funding through the Swedish Research Council under the grant no 2021-00180.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The association between type 2 diabetes and attention- deficit/hyperactivity disorder: A systematic review, meta-analysis, and population-based sibling study

  • Zhang, Le
  • Yao, Honghui
  • Jendle, Johan
  • Ribases Haro, Marta
  • Garcia-Argibay, Miguel
  • Li, Lin
  • Du Rietz, Ebba
  • Ramos-Quiroga, Josep Antoni
Attention deficit hyperactivity disorder; Cardiovascular risk factors; Type 2 diabetes, Trastorno por déficit de atención con hiperactividad; Factores de riesgo cardiovascular; Diabetes tipo 2, Trastorn per dèficit d'atenció amb hiperactivitat; Factors de risc cardiovascular; Diabetis tipus 2, We conducted a systematic review and a meta-analysis to quantitatively summarize evidence on the association between attention-deficit/hyperactivity disorder (ADHD) and type 2 diabetes (T2D). Moreover, a register-based sibling study was conducted to simultaneously control for confounding factors. A systematic search identified four eligible observational studies (N = 5738,287). The meta-analysis showed that individuals with ADHD have a more than doubled risk of T2D when considering adjusted estimates (OR=2.29 [1.48–3.55], d=0.46). Results from the register-based Swedish data showed a significant association between ADHD and T2D (HR=2.35 [2.14–2.58]), with substance use disorder, depression, and anxiety being the main drivers of the association, and cardiovascular and familiar risk playing a smaller role. While results from the meta-analysis provide evidence for an increased risk of T2D in individuals with ADHD, the register-based analyses show that the association between ADHD and T2D is largely explained by psychiatric comorbidities. Pending further evidence of causal association, our findings suggest that early identification and treatment of ADHD comorbidities might greatly reduce the risk of developing T2D in individuals with ADHD., The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965381. This report reflects only the author’s view, and the European Union is not responsible for any use that may be made of the information it contains. Henrik Larsson acknowledges financial support from the Swedish Research Council (2018-02599) and the Swedish Brain Foundation (FO2021-0115). Zheng Chang acknowledges financial support from the Swedish Council for Health, Working Life and Welfare (2019-00176). Ebba Du Rietz was supported by grant PD20-0036 from the Swedish Society for Medical Research (SSMF), Funds from the Strategic Research Program in Epidemiology at Karolinska Institutet, Fredrik & Ingrid Thurings Stiftelse and Fonden för Psykisk Hälsa.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Remote monitoring of wide-ranging real-world changes in adults following ADHD medication initiation

  • Zhang, Yuezhou
  • Veerakanjana, Kanyakorn
  • Sankesara, Heet
  • Marriott, Hannah
  • Barnes, Alice
  • Denyer, Hayley
  • Ramos-Quiroga, Josep Antoni
Remote monitoring; ADHD, Monitorització remota; TDAH, Monitorización remota; TDAH, While attention-deficit/hyperactivity disorder (ADHD) medication is effective for core symptoms, its broader and progressive impacts remain underexplored. This study evaluated real-world changes in ADHD symptoms and impairments, co-occurring psychiatric symptoms, physical measures, and health behaviors following ADHD medication initiation in adults. Data were drawn from a remote monitoring cohort recruited from adult ADHD clinic waiting lists in the United Kingdom and Spain. Participants completed 4-weekly smartphone-based self-reports and continuously wore a wearable device to monitor behaviors such as physical activity and sleep. We additionally developed novel wearable-derived features to approximate restlessness. A subset of 176 participants with valid baseline (off-medication) and up to three 4-weekly on-medication assessments was included. Compared to the off-medication phase, the on-medication phase was significantly associated with improvements in ADHD symptoms and impairments, as well as reductions in depression, anxiety, irritability, and aggression. Additional changes included reduced alcohol use, healthier diet, elevated heart rate, lower blood pressure, reduced waist circumference, increased physical activity, less restlessness, and improved sleep quality. Several domains showed significant progressive changes, including continued improvements in ADHD symptoms, impairments, and irritability; rising heart rate; declining body weight; and delayed sleep timing. These findings suggest ADHD medication in adults is associated with broad real-world benefits alongside some potential concerns, such as elevated heart rate and delayed sleep. This study highlights the potential of remote monitoring technologies to capture multidimensional treatment responses in daily life and provides a foundation for future research to support both clinical care and self-management in ADHD., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965381. This report reflects only the authors’ views and the Commission is not responsible for any use that may be made of the information it contains.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Genetic architecture of ADHD and overlap with other psychiatric disorders and cognition-related phenotypes

  • hartman, catharina
  • Larsson, Henrik
  • Ribases, Marta
  • Mitjans, Marina
  • Soler Artigas, María
  • Demontis, Ditte
  • Ramos-Quiroga, Josep Antoni
Trastorno por déficit de atención e hiperactividad; Comorbilidad; Genética de trastornos cruzados, Trastorn per dèficit d'atenció i hiperactivitat; Comorbiditat; Genètica de trastorns creuats, Attention-deficit/hyperactivity disorder; Comorbidity; Cross-disorder genetics, Attention-deficit/hyperactivity disorder (ADHD) co-occurs with many other psychiatric disorders and traits. In this review, we summarize and interpret the existing literature on the genetic architecture of these comorbidities based on hypothesis-generating approaches. Quantitative genetic studies indicate that genetic factors play a substantial role in the observed co-occurrence of ADHD with many different disorders and traits. Molecular genetic correlations derived from genome-wide association studies and results of studies based on polygenic risk scores confirm the general pattern but provide effect estimates that are smaller than those from twin studies. The identification of the specific genetic variants and biological pathways underlying co-occurrence using genome-wide approaches is still in its infancy. The first analyses of causal inference using genetic data support causal relationships between ADHD and comorbid disorders, although bidirectional effects identified in some instances point to complex relationships. While several issues in the methodology and inferences from the results are still to be overcome, this review shows that the co-occurrence of ADHD with many psychiatric disorders and traits is genetically interpretable., This research has received funding from the EU’s Horizon 2020 research and innovation program under grant agreements no. 667302 (CoCA), 728018 (Eat2beNICE) and 2020604 (TIMESPAN) and from the ECNP Network ‘ADHD across the Lifespan' (https://www.ecnp.eu/researchinnovation/ECNP-networks/List-ECNP-Networks/). B Cormand has also been supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (PID2021-1277760B-I100), the Ministerio de Sanidad, Servicios Sociales e Igualdad/Plan Nacional Sobre Drogas (PNSD-2017I050), Fundació La Marató de TV3 (202218-31), Generalitat de Catalunya/AGAUR (2021-SGR-1093), ICREA Academia 2021 and the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 841899 (GRASAD) and 101028810 (ATTENTIVE). M Ribasés was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE), by the Instituto de Salud Carlos III (PI20/00041, CP09/00119 and CPII15/00023), by the Pla estratègic de recerca i innovació en salut (PERIS), Generalitat de Catalunya (METAL-Cat; SLT006/17/287), by the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2017SGR1461) and by Fundació La Marató de TV3 (202228-30, 202228-31). JA Ramos-Quiroga was also supported by the European Union H2020 Programme (H2020/2014–2020) under grant agreement no. 848228 (DISCOvERIE). M Mitjans was supported by Horizon 2020 Marie Sklodowska-Curie Individual Fellowship from the European Commission under grant agreement no. 841899 (GRASAD), the MCIN/AEI/10.13039/501100011033 and the European Union “NextGenerationEU”/PRTR” (RYC2021-033573-I), Ministerio de Ciencia e Innovación (PID2022-139740OA-100) and the Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR, Generalitat de Catalunya (2021-SGR-1093). M Soler Artigas was supported by the Instituto de Salud Carlos III (P19/01224, PI22/00464 and CP22/00128) and by the European Regional Development Fund. B Franke and A Reif were also supported by funding from the EU’s Horizon 2020 research and innovation program under grant agreement no. 847879 (PRIME). B Franke also received relevant funding from the Netherlands Organization for Scientific Research (NWO) for the GUTS project (grant 024.005.011). D Demontis is supported by the Novo Nordisk Foundation (NNF20OC0065561 and NNF21SA0072102), the Lundbeck Foundation (R344-2020-1060), the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 965381 (TIMESPAN). AD Børglum was supported by the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003). Research reported in this publication was also supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R01MH124851. The content of the publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or any of the other funding organisations mentioned here.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

ADHD Remote Technology study of cardiometabolic risk factors and medication adherence (ART-CARMA): a multi-centre prospective cohort study protocol

  • Folarin, Amos A
  • Ramos Sayalero, Carolina
  • Nemeth, Petra
  • Denyer, Hayley
  • Bilbow OBE, Andrea
  • Ramos-Quiroga, Josep Antoni
Attention deficit hyperactivity disorder; Digital phenotyping; Remote monitoring, Trastorno por déficit de atención con hiperactividad; Fenotipado digital; Monitoreo remoto, Transtorn per dèficit d'atenció amb hiperactivitat; Fenotipat digital; Monitorització remota, Background Emerging evidence points at substantial comorbidity between adult attention deficit hyperactivity disorder (ADHD) and cardiometabolic diseases, but our understanding of the comorbidity and how to manage cardiometabolic disease in adults with ADHD is limited. The ADHD Remote Technology study of cardiometabolic risk factors and medication adherence (ART-CARMA) project uses remote measurement technology to obtain real-world data from daily life to assess the extent to which ADHD medication treatment and physical activity, individually and jointly, may influence cardiometabolic risks in adults with ADHD. Our second main aim is to obtain valuable real-world data on adherence to pharmacological treatment and its predictors and correlates during daily life from adults with ADHD. Methods ART-CARMA is a multi-site prospective cohort study within the EU-funded collaboration ‘TIMESPAN’ (Management of chronic cardiometabolic disease and treatment discontinuity in adult ADHD patients) that will recruit 300 adults from adult ADHD waiting lists. The participants will be monitored remotely over a period of 12 months that starts from pre-treatment initiation. Passive monitoring, which involves the participants wearing a wrist-worn device (EmbracePlus) and downloading the RADAR-base Passive App and the Empatica Care App on their smartphone, provides ongoing data collection on a wide range of variables, such as physical activity, sleep, pulse rate (PR) and pulse rate variability (PRV), systolic peaks, electrodermal activity (EDA), oxygen saturation (SpO2), peripheral temperature, smartphone usage including social connectivity, and the environment (e.g. ambient noise, light levels, relative location). By combining data across these variables measured, processes such as physical activity, sleep, autonomic arousal, and indicators of cardiovascular health can be captured. Active remote monitoring involves the participant completing tasks using a smartphone app (such as completing clinical questionnaires or speech tasks), measuring their blood pressure and weight, or using a PC/laptop (cognitive tasks). The ART system is built on the RADAR-base mobile-health platform. Discussion The long-term goal is to use these data to improve the management of cardiometabolic disease in adults with ADHD, and to improve ADHD medication treatment adherence and the personalisation of treatment., The ART-CARMA study has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965381. This communication reflects the views of the authors, and the European Commission is not responsible for any use that may be made of the information it contains. HD is supported by the UK Medical Research Council (MR/N013700/1) and King’s College London member of the MRC Doctoral Training Partnership in Biomedical Sciences.